174607-68-2

Basic information

• Product Name: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)
• Synonyms: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol);(R)-4-Benzyl Albuterol;Levalbuterol Related CoMpound F;(1R)-2-(tert-butylamino)-1-[3-(hydroxymethyl)-4-phenylmethoxyphenyl]ethanol
• CAS NO: 174607-68-2
• Molecular Formula: C₂₀H₂₇NO₃
• Molecular Weight: 329.43328
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 174607-68-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 510.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.120±0.06 g/cm3(Predicted)
• PKA: 13.97±0.20(Predicted)
• CAS DataBase Reference: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)(CAS DataBase Reference)
• NIST Chemistry Reference: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)(174607-68-2)
• EPA Substance Registry System: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)(174607-68-2)

Safety Data

• Hazardous Substances Data: 174607-68-2(Hazardous Substances Data)

Usage

Uses

(R)-4-Benzyl Albuterol is an isomer of 4-Benzyl Albuterol (B224750), an precursor of Albuterol (A514500).

Upstream product

• 39235-60-4 4'-benzyloxy-3'-acetoxymethylacetophenone 
• 39235-61-5 4'-benzyloxy-3'-(acetoxymethyl)bromoacetophenone 
• 1005420-22-3 (R)-4-benzyl salbutamol formate 
• 1005420-21-2 4-nitro tartranilic acid salt of (R)-isomer of 4-benzyl salbutamol 

Downstream Products

• 324000-05-7 salbutamol sulphate 
• 50293-91-9 levosalbutamol hydrochloride 

Relevant articles and documents

Preparation method of leverbuterol and its salt

The invention provides a method for cheap and effective preparation of leverbuterol in industry. The method consists of: taking protected 4-hydroxy-3-hydroxymethyl acetophenone as the raw material to react with bromine to generate acyl or alkyl protected 4-hydroxy-3-hydroxymethyl bromoacetophenone, under in the presence of (1R, 2S)-(+)-indanol as a catalyst, using borane to conduct chiral reduction on carbonyl in the structural formula to obtain R configuration acyl or alkyl protected 4-hydroxy-3-hydroxymethyl alpha bromo phenethyl alcohol, then carrying out reaction with tert-butylamine to generate acyl or alkyl protected 4-hydroxy-3-hydroxymethyl phenylaminoethanol, and finally removing the acyl protecting group to obtain leverbuterol free alkali, and letting the free alkali and acid form a salt. The finished product has optical purity up to 99.9%, and no other chiral resolution way is needed for purification.

A PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

A process for the preparation of optically pure R (-) salbutamol of formula (6) and its pharmaceutically acceptable salts by using a (+) 4-nitro tartranilic acid as the resolving agent and a binary solvent system comprising alkyl acetate and C1 to C4 branched or normal chain alcohol for dissolution of the racemic mixture and resolving agent and purification of the 4-nitro tartranilic acid salt of R (-) salbutamol. 4-nitro tartranilic acid salt of R (-) salbutamol is converted into formic acid salt of R(-) 4-benzyl salbutamol followed by basification and debenzylation to form optically pure R(-) salbutamol. Optically pure (R) -salbutamol is obtained in good yield and high purity. The optically pure R(-) salbutamol is optionally converted into pharmaceutically acceptable salts.